Adverse Events of SARS-CoV-2 Therapy: A Pharmacovigilance Study of the FAERS Database

被引:3
|
作者
Pannu, Viraaj [1 ]
Udongwo, Ndausung [1 ]
Imburgio, Steven [1 ]
Johal, Anmol [1 ]
Mararenko, Anton [1 ]
Pozdniakova, Helen [1 ]
Amin, Tasnuva [1 ]
Patel, Swapnil [1 ]
Hossain, Mohammad [1 ]
Mushtaq, Arman [1 ]
Liu, Edward [2 ]
Fune, Jose M. [2 ]
Heaton, Joseph [1 ]
机构
[1] Jersey Shore Univ, Dept Internal Med, Med Ctr, Neptune City, NJ 07753 USA
[2] Jersey Shore Univ, Dept Infect Dis, Med Ctr, Neptune City, NJ 07753 USA
关键词
COVID-19; FAERS; adverse events; antivirals; nirmatrelvir; ritonavir;
D O I
10.1177/10600280231169256
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Over the past 2 years of the several strategies recommended to help fight COVID-19, nirmatrelvir/ritonavir is a novel drug shown in the EPIC-HR phase 2 to 3 clinical trial to lower COVID-19-related death or hospitalization at day 28 when compared with placebo. Objective: Our study's aim was to explore the reported adverse events (AEs) associated with nirmatrelvir/ritonavir use for COVID-19. Method: We conducted a retrospective analysis using the FDA Adverse Event Reporting System (FAERS) database for AEs, listing nirmatrelvir/ritonavir as the primary drug between January and June 2022. The primary outcome was the incidence of reported AEs associated with nirmatrelvir/ritonavir. The OpenFDA database was queried using Python 3.10 to collect the AEs and Stata 17 was used to analyze the database. Adverse events were analyzed by associated medication, with "Covid-19" excluded. Results: A total of 8098 reports were identified between January and June 2022. Most reported complaints in the AE system were COVID-19 and disease recurrence. The most common symptomatic AEs were dysgeusia, diarrhea, cough, fatigue, and headache. Event rates significantly rose between April and May. Disease recurrence and dysgeusia were the most commonly reported complaints for the top 8 concomitant drugs identified. Cardiac arrest, tremor, akathisia, and death were reported in 1, 3, 67, and 5 cases, respectively. Conclusions and Relevance: This is the first retrospective study done on reported AEs associated with nirmatrelvir/ritonavir use for COVID-19. COVID-19 and disease recurrence were the most reported AEs. Further monitoring of the FAERS database is warranted to periodically reassess the safety profile of this medication.
引用
收藏
页码:105 / 109
页数:5
相关论文
共 50 条
  • [1] Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
    Zhao, Hui
    Li, Jun-Min
    Li, Zi-Ran
    Zhang, Qian
    Zhong, Ming-Kang
    Yan, Ming-Ming
    Qiu, Xiao-Yan
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [2] Adverse events associated with oseltamivir and baloxavir marboxil in against influenza virus therapy: A pharmacovigilance study using the FAERS database
    Zhou, Yixia
    Jin, Liuyin
    Lai, Xiaolong
    Li, Yang
    Sheng, Lindan
    Xie, Guoming
    Fang, Jianjiang
    PLOS ONE, 2024, 19 (11):
  • [3] The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database
    Wang, Xiaogan
    Chen, Hao
    Han, Shuangshuang
    Li, Lingbo
    Chen, Hongjin
    Yang, Bolin
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [4] Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
    Li, Yun
    Li, Hang
    Xiang, Zhongyuan
    HELIYON, 2024, 10 (06)
  • [5] Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database
    Mikami, Takahisa
    Liaw, Bobby
    Asada, Mizuho
    Niimura, Takahiro
    Zamami, Yoshito
    Green-LaRoche, Deborah
    Pai, Lori
    Levy, Michael
    Jeyapalan, Suriya
    JOURNAL OF NEURO-ONCOLOGY, 2021, 152 (01) : 135 - 144
  • [6] Abrocitinib-associated adverse events: a real-world pharmacovigilance study using the FAERS database
    Sun, Yu
    Xu, Tao
    Zhu, Suyan
    Xu, Hongbin
    EXPERT OPINION ON DRUG SAFETY, 2025, 24 (02) : 233 - 239
  • [7] Neuroimmunological Adverse Events Associated With Immune Checkpoint Inhibitor: A Retrospective, Pharmacovigilance study Using FAERS Database
    Mikami, Takahisa
    Liaw, Bobby
    Asada, Mizuho
    Niimura, Takahiro
    Zamami, Yoshito
    Green-LaRoche, Deborah
    Pai, Lori
    Levy, Michael
    Jeyapalan, Suriya
    NEUROLOGY, 2021, 96 (15)
  • [8] Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database
    Takahisa Mikami
    Bobby Liaw
    Mizuho Asada
    Takahiro Niimura
    Yoshito Zamami
    Deborah Green-LaRoche
    Lori Pai
    Michael Levy
    Suriya Jeyapalan
    Journal of Neuro-Oncology, 2021, 152 : 135 - 144
  • [9] Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database
    Wu, Shi-Nan
    Huang, Caihong
    Wang, Yu-Qian
    Li, Xiang
    Zhang, Si-Qi
    Chen, Xiao-Dong
    Qin, Dan-Yi
    Zhu, Linfangzi
    Wen, Jia-Yi
    Luo, Na-Chuan
    Hu, Jiaoyue
    Liu, Zuguo
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2024, 15
  • [10] Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database
    Liu, Rongqiang
    Chen, Yukai
    Wu, Shi-Nan
    Ma, Wangbin
    Qiu, Zhendong
    Wang, Jianguo
    Xu, Ximing
    Chen, Chen
    Wang, Weixing
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2024, 15